Valeant in talks to sell Salix unit in $10 billion dealStaff Writer | November 2, 2016
Valeant Pharmaceuticals is in talks with third parties to sell its Salix stomach-drug business and other assets.
Selling Takeda is continuously considering various options
Some said Takeda is one of the parties. "Takeda is continuously considering various options aiming to accelerate its growth. At this point, we have nothing to be disclosed."
The Japanese bourse earlier in the day suspended trading in Takeda shares until the company released its statement.
The deal could raise as much as $10 billion for the indebted drugmaker, people familiar with the matter told Reuters. ■